VM

VHCP Management II, LLC

High-turnover traderMomentum followerConcentrated strategy

Total reported value

$379.4M

Reporting period: 2019-12-31 · Number of holdings: 20

VHCP Management II, LLC disclosed 20 holdings in its latest 13F filing for the period ending 2019-12-31, with total reported value of $379.4M and a quarterly turnover rate of 93.6%.

Personality snowflake

Concentration
86.78
Portfolio Stability
93.57
Momentum/Contrarian
100
Sector conviction
0
Diversification
40
Sizing Uniformity
81.25

Recent moves

  • Add CNST

    +106.5%　$66.0M

  • Add AXSM

    -12.0%　$63.2M

  • Trim H5861P103

    -30.1%　-$12.8M

  • Trim BHVN

    -35.1%　-$4.5M

  • Trim SWAVUSD

    -55.3%　-$6.7M

  • Trim PTGX

    -92.5%　-$4.9M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1TXG10x Genomics Inc-class AStock-Other35.91%+1.60%—
2AXSMAxsome Therapeutics INCStock-Healthcare21.42%+14.53%-11.98%
3CNSTConstellation PharmaceuticalStock-Other18.64%+16.85%+106.51%
4BHVNBiohaven Ltd.Stock-Other6.64%-4.69%-35.07%
5SWAVUSDShockwave Medical INCStock-Other3.34%-4.03%-55.32%
6OPHTEURIveric Bio INCStock-Other2.27%+2.27%NEW
74XC1Kalvista Pharmaceuticals INCStock-Other1.72%+0.05%-2.82%
8✓ Obseva SAStock-Other1.58%-5.57%-30.14%
9✓ Mersana Therapeutics INCStock-Other1.39%+1.39%NEW
10SPROSpero Therapeutics INCStock-Other1.20%-0.72%—
11RLMDRelmada Therapeutics INCStock-Other1.18%+1.18%NEW
12ADVMCHFAdverum Biotechnologies INCStock-Other1.16%+1.16%NEW
13MRNSUSDMarinus Pharmaceuticals INCStock-Other0.85%-0.02%—
14FTSVEURForty Seven INCStock-Other0.81%+0.81%NEW
15MISTMilestone Pharmaceuticals InStock-Other0.63%-0.43%—
16NXTCEURNextcure INCStock-Other0.54%+0.54%NEW
17✓ Myovant Sciences LTDStock-Other0.31%+0.31%NEW
18ETNBGBP89bio INCStock-Other0.29%+0.29%NEW
19BLPHEURBellerophon Therapeutics INCStock-Other0.06%-0.70%-84.12%
20PTGXProtagonist Therapeutics INCStock-Other0.06%-1.89%-92.45%

Holding changes this quarter

VHCP Management II, LLC's most significant position changes for 2019-12-31: Sold out: Ascendis Pharma A/S (ASND); Sold out: Ra Pharmaceuticals INC (RARXEUR); New buy: Iveric Bio INC (OPHTEUR); Sold out: Biocryst Pharmaceuticals INC (BCRX); New buy: Mersana Therapeutics INC.

Position changes disclosed by VHCP Management II, LLC for the quarter ending 2019-12-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1CNSTConstellation Pharmaceutical+16.9%+106.51%Add
2AXSMAxsome Therapeutics INC+14.5%-11.98%Trim
3TXG10x Genomics Inc-class A+1.6%—Unchanged
44XC1Kalvista Pharmaceuticals INC+0.1%-2.82%Trim
5MRNSUSDMarinus Pharmaceuticals INC0%—Unchanged
6MISTMilestone Pharmaceuticals In-0.4%—Unchanged
7BLPHEURBellerophon Therapeutics INC-0.7%-84.12%Trim
8SPROSpero Therapeutics INC-0.7%—Unchanged
9PTGXProtagonist Therapeutics INC-1.9%-92.45%Trim
10SWAVUSDShockwave Medical INC-4%-55.32%Trim
11BHVNBiohaven Ltd.-4.7%-35.07%Trim
12✓ Obseva SA-5.6%-30.14%Trim
13ASNDAscendis Pharma A/S—EXITSold out
14RARXEURRa Pharmaceuticals INC—EXITSold out
15OPHTEURIveric Bio INC—NEWNew buy
16BCRXBiocryst Pharmaceuticals INC—EXITSold out
17✓ Mersana Therapeutics INC—NEWNew buy
18KNSAKiniksa Pharmaceuticals International, plc—EXITSold out
19LJPCLa Jolla Pharmaceutical Co—EXITSold out
20RLMDRelmada Therapeutics INC—NEWNew buy
21ADVMCHFAdverum Biotechnologies INC—NEWNew buy
221T7Tricida INC—EXITSold out
23FTSVEURForty Seven INC—NEWNew buy
24NXTCEURNextcure INC—NEWNew buy
25✓ Myovant Sciences LTD—NEWNew buy
26ETNBGBP89bio INC—NEWNew buy
27RDUSEURRadius Health INC—EXITSold out
28PTIEURProteostasis Therapeutics In—EXITSold out
29✓ Prevail Therapeutics INC—EXITSold out

FAQ

What is VHCP Management II, LLC and what type of investor is it?
VHCP Management II, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2019-12-31), the firm manages a tracked equity portfolio valued at approximately $379.4M, spread across 20 disclosed positions.
What are VHCP Management II, LLC's largest equity positions?
Based on the latest 13F filing, VHCP Management II, LLC's top holdings by market value are: 1. 10x Genomics Inc-class A (TXG) — $136.2M (35.9%) 2. Axsome Therapeutics INC (AXSM) — $81.2M (21.4%) 3. Constellation Pharmaceutical (CNST) — $70.7M (18.6%) 4. Biohaven Ltd. (BHVN) — $25.2M (6.6%) 5. Shockwave Medical INC (SWAVUSD) — $12.7M (3.3%)
What changes did VHCP Management II, LLC make in its most recent portfolio filing?
In the latest reported quarter, VHCP Management II, LLC made 25 notable position adjustments: 8 new positions were initiated, 1 existing holdings were added to, 7 positions were partially reduced, and 9 were completely exited. The largest of these moves: Sold out: Ascendis Pharma A/S (ASND); Sold out: Ra Pharmaceuticals INC (RARXEUR); New buy: Iveric Bio INC (OPHTEUR); Sold out: Biocryst Pharmaceuticals INC (BCRX); New buy: Mersana Therapeutics INC
What sectors does VHCP Management II, LLC focus on?
VHCP Management II, LLC is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%